Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., has launched a Regulation D 506(c) offering to raise up to $5.0 million. The capital raise will fund growth initiatives and establish a path toward a potential IPO, without diluting Quantum BioPharma shareholders.
Quantum BioPharma maintains a 25% ownership stake in Unbuzzd through an anti-dilution provision until Unbuzzd reaches a $1 billion valuation. Unbuzzd has partnered with MZ Digital and Dealmaker for the capital raise campaign, accepting both traditional and cryptocurrency payments through ALT5 Pay's platform.
Unbuzzd is led by CEO John Duffy, former Coca-Cola VP, and Board Co-Chair Gerry David, former CEO of Celsius Holdings. The company produces unbuzzd™, a functional beverage designed to accelerate alcohol metabolism and reduce hangover symptoms.
Quantum BioPharma (NASDAQ: QNTM) ha annunciato che la sua licenziataria, Unbuzzd Wellness Inc., ha avviato un'offerta Regulation D 506(c) per raccogliere fino a 5,0 milioni di dollari. I fondi raccolti saranno destinati a iniziative di crescita e a tracciare un percorso verso una possibile IPO, senza diluire la partecipazione degli azionisti di Quantum BioPharma.
Quantum BioPharma detiene una quota di proprietà del 25% in Unbuzzd grazie a una clausola anti-diluizione fino a quando Unbuzzd non raggiungerà una valutazione di 1 miliardo di dollari. Unbuzzd ha collaborato con MZ Digital e Dealmaker per la campagna di raccolta fondi, accettando pagamenti sia tradizionali che in criptovalute tramite la piattaforma ALT5 Pay.
Unbuzzd è guidata dal CEO John Duffy, ex vicepresidente di Coca-Cola, e dal Co-Presidente del Consiglio Gerry David, ex CEO di Celsius Holdings. L’azienda produce unbuzzd™, una bevanda funzionale progettata per accelerare il metabolismo dell’alcol e ridurre i sintomi del postumi della sbornia.
Quantum BioPharma (NASDAQ: QNTM) anunció que su licenciataria, Unbuzzd Wellness Inc., ha lanzado una oferta Regulation D 506(c) para recaudar hasta 5,0 millones de dólares. Los fondos recaudados financiarán iniciativas de crecimiento y establecerán un camino hacia una posible oferta pública inicial (IPO), sin diluir a los accionistas de Quantum BioPharma.
Quantum BioPharma mantiene una participación del 25% en Unbuzzd mediante una cláusula antidilución hasta que Unbuzzd alcance una valoración de 1.000 millones de dólares. Unbuzzd se ha asociado con MZ Digital y Dealmaker para la campaña de recaudación de capital, aceptando pagos tanto tradicionales como en criptomonedas a través de la plataforma ALT5 Pay.
Unbuzzd está dirigida por el CEO John Duffy, ex vicepresidente de Coca-Cola, y el copresidente del consejo Gerry David, ex CEO de Celsius Holdings. La compañía produce unbuzzd™, una bebida funcional diseñada para acelerar el metabolismo del alcohol y reducir los síntomas de la resaca.
Quantum BioPharma (NASDAQ: QNTM)는 라이선스 업체인 Unbuzzd Wellness Inc.가 최대 5백만 달러를 모금하는 Regulation D 506(c) 공모를 시작했다고 발표했습니다. 이번 자본 조달은 성장 이니셔티브에 자금을 지원하고 Quantum BioPharma 주주들의 지분 희석 없이 잠재적인 IPO로 가는 길을 마련할 예정입니다.
Quantum BioPharma는 Unbuzzd가 10억 달러 가치 평가에 도달할 때까지 희석 방지 조항을 통해 Unbuzzd의 25% 소유 지분을 유지하고 있습니다. Unbuzzd는 MZ Digital 및 Dealmaker와 협력하여 자본 조달 캠페인을 진행하며, ALT5 Pay 플랫폼을 통해 전통적인 결제와 암호화폐 결제 모두를 수용합니다.
Unbuzzd는 전 코카콜라 부사장인 CEO John Duffy와 전 Celsius Holdings CEO인 이사회 공동 의장 Gerry David가 이끌고 있습니다. 이 회사는 알코올 대사를 촉진하고 숙취 증상을 완화하는 기능성 음료인 unbuzzd™를 생산합니다.
Quantum BioPharma (NASDAQ: QNTM) a annoncé que sa licenciée, Unbuzzd Wellness Inc., a lancé une offre Regulation D 506(c) visant à lever jusqu'à 5,0 millions de dollars. Cette levée de fonds financera des initiatives de croissance et ouvrira la voie à une éventuelle introduction en bourse, sans diluer les actionnaires de Quantum BioPharma.
Quantum BioPharma détient une participation de 25% dans Unbuzzd grâce à une clause antidilution jusqu'à ce que Unbuzzd atteigne une valorisation d'un milliard de dollars. Unbuzzd s'est associé à MZ Digital et Dealmaker pour la campagne de levée de fonds, acceptant à la fois les paiements traditionnels et en cryptomonnaies via la plateforme ALT5 Pay.
Unbuzzd est dirigée par le PDG John Duffy, ancien vice-président de Coca-Cola, et le coprésident du conseil Gerry David, ancien PDG de Celsius Holdings. La société produit unbuzzd™, une boisson fonctionnelle conçue pour accélérer le métabolisme de l'alcool et réduire les symptômes de la gueule de bois.
Quantum BioPharma (NASDAQ: QNTM) gab bekannt, dass sein Lizenznehmer, Unbuzzd Wellness Inc., ein Regulation D 506(c)-Angebot gestartet hat, um bis zu 5,0 Millionen US-Dollar zu sammeln. Die Kapitalerhöhung soll Wachstumsinitiativen finanzieren und einen Weg zu einem möglichen Börsengang ebnen, ohne die Aktionäre von Quantum BioPharma zu verwässern.
Quantum BioPharma hält über eine Verwässerungsschutzklausel bis zum Erreichen einer Bewertung von 1 Milliarde US-Dollar eine 25%ige Eigentumsbeteiligung an Unbuzzd. Unbuzzd arbeitet für die Kapitalbeschaffung mit MZ Digital und Dealmaker zusammen und akzeptiert sowohl traditionelle als auch Kryptowährungszahlungen über die Plattform von ALT5 Pay.
Unbuzzd wird von CEO John Duffy, ehemaliger Vizepräsident bei Coca-Cola, und dem Co-Vorsitzenden des Vorstands Gerry David, ehemaliger CEO von Celsius Holdings, geleitet. Das Unternehmen stellt unbuzzd™ her, ein funktionales Getränk, das den Alkoholstoffwechsel beschleunigt und Katerbeschwerden lindert.
- Quantum BioPharma maintains protected 25% ownership stake until $1B valuation
- Strong leadership team with former Coca-Cola VP and Celsius Holdings CEO
- Non-dilutive opportunity for Quantum BioPharma shareholders
- Multiple payment options including cryptocurrency through ALT5 Pay
- Capital raise limited to accredited investors under Reg D 506(c)
- IPO timeline and success not guaranteed
Insights
Quantum BioPharma's licensee Unbuzzd launching $5M capital raise without diluting QNTM shareholders; maintains 25% ownership until $1B valuation.
Quantum BioPharma (NASDAQ: QNTM) has announced that its licensee Unbuzzd Wellness Inc. is launching a Regulation D 506(c) offering to raise up to
The most significant aspect of this announcement is Quantum's protected position through an anti-dilution provision that maintains its
Unbuzzd's product is positioned in the functional beverage market, specifically targeting alcohol metabolism and hangover reduction. The company has assembled notable industry experience, including former Coca-Cola executive John Duffy as CEO and Gerry David (former CEO of Celsius Holdings) as Board Co-Chair. This executive team brings significant beverage industry expertise that could accelerate market penetration.
The capital raise is designed to fund direct-to-consumer expansion, distributor relationships, and retail presence. Should Unbuzzd successfully execute its growth strategy and achieve a public listing, Quantum would benefit from the ability to access non-dilutive capital through its ownership stake. However, investors should note this represents potential future value rather than immediate financial impact to Quantum's operations.
While the press release outlines aspirational goals including a possible IPO, the near-term tangible benefit to Quantum remains limited as Unbuzzd is still in the capital-raising stage with unproven market performance for its beverage product.
This Offering Will Not Dilute Quantum BioPharma Shareholders
TORONTO, July 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced that Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM – the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms – today announced the launch of its previously announced Regulation D 506(c) offering to raise up to US
This will not impact or dilute Quantum BioPharma shareholders. Quantum BioPharma maintains an anti-dilution provision which ensures its ownership in Unbuzzd Wellness Inc. is
Unbuzzd has partnered with MZ Digital, a global leader in marketing, and Dealmaker, a leading online platform for raising capital to conduct the capital raise campaign. The Regulation D offering allows Unbuzzd to raise capital by selling and issuing securities to accredited investors without a cap on the amount raised. Investments can be made with traditional payments or with cryptocurrency payments: the latter through ALT5 Pay’s digital payments platform.
To learn more about the offering and invest, visit this link Unbuzzd Invest.
John Duffy, CEO of Unbuzzd Wellness, stated, "This capital raise allows us to introduce investors to a new era in functional beverages aimed at supporting overall wellness after social occasions. unbuzzd is a refreshing, science-backed beverage that helps people feel more refreshed and alert after drinking. This offering will help us raise the necessary capital to support direct-to-consumer, distributor, and retail expansion plans.” Mr. Duffy has over twenty years of leadership experience in the beverage industry, including as former VP of Marketing Assets and VP of National Sales at Coca-Cola.
Gerry David, Board Co-Chair and former CEO of Celsius Holdings with their bestselling energy drink Celsius Energy, added, "Together with our partners MZ Digital, a global leader in online marketing, and Dealmaker, a leading online platform for raising capital, we are excited to launch this offering to build our company and sales momentum, and position Unbuzzd for a future initial public offering."
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of
For more information on Quantum BioPharma, please visit www.quantumbiopharma.com.
About Unbuzzd Wellness Inc.
Unbuzzd Wellness inc., a non-trading but fully reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. unbuzzd has been developed by a world-class R&D team in pharmacology and medicine, with a commitment to innovation and quality. A proprietary blend of vitamins, minerals, and herbs, unbuzzd helps your body process alcohol faster, restore mental alertness, and improve cognition so you can drink responsibly and drink refreshingly. unbuzzd appeals to a broad target audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day.
Scientifically backed by a recently completed double-blind, randomized, placebo-controlled crossover design clinical trial, unbuzzd dramatically accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration ("BAC"), restores mental clarity, and reduces the symptoms of intoxication, impairment and hangover. Key findings from the clinical trial include:
- Accelerated Alcohol Metabolism: unbuzzd dramatically and rapidly reduced blood alcohol concentration in study participants. The rate at which BAC was lowered was, on average for most participants, more than 40 percent faster within 30 minutes of consuming unbuzzd compared to control subjects.
- Rapid Improvements in Alertness: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming unbuzzd. Participants felt more alert and made fewer cognitive errors within 30 minutes of consuming unbuzzd, significantly outperforming placebo results.
- Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. This result was statistically significant.
- Reduced Perceived Impairment and Mental Fatigue: unbuzzd helped alleviate perceived impairment and mental fatigue caused by alcohol intoxication.
- Hangover Relief: Participants in this study noted a statistically significant reduction in hangover symptoms. This included reduced cognitive and physical impairment, and reduced headache compared to placebo results, at both four hours (67 percent reduction in headache severity) and eight hours after consuming unbuzzd.
- No Side Effects: unbuzzd was well-tolerated by all study participants, with no reported adverse side effects.
The full press release of the clinical trial can be found here.
unbuzzd ready-to-mix powder sticks are available in 3-pack and 18-pack formats at https://unbuzzd.com. unbuzzdTM is a registered trademark of Unbuzzd Wellness Inc.
Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE.
For more information on Unbuzzd Wellness Inc. please visit www.unbuzzd.com
8-pack, 18-pack, and 3-pack formats of the unbuzzd ready-to-mix powder sticks
Forward-Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such.
Forward-looking information in this press release are based on certain assumptions and expected future events.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e45d0b31-871c-4871-8116-08008306ce76
FAQ
How much is Unbuzzd Wellness planning to raise in its Regulation D offering?
What is Quantum BioPharma's ownership stake in Unbuzzd Wellness?
Who are the key executives leading Unbuzzd Wellness?
How will this capital raise affect QNTM shareholders?
What payment methods are accepted for the Unbuzzd Wellness capital raise?
